Payment overview · 2025
General Payments
$41.75
2 reported records · 1 companies
Healthcare provider profile · identity verified
Ida Hess, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · HERRIN, IL · NPI 1831264639
Verified facts
What the public records show
CMS Open Payments records show Ida Hess, CNP received $41.75 in general payments during 2025 across 2 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $41.75 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $41.75 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $41.75 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 538 | 66 |
| Potassium Chloride | Potassium Chloride | 469 | 67 |
| Eliquis | Apixaban | 460 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 274 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 39 |
| Donepezil Hcl | Donepezil Hcl | 202 | 30 |
| Tramadol Hcl | Tramadol Hcl | 190 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 21 |
| Gabapentin | Gabapentin | 174 | 28 |
| Carvedilol | Carvedilol | 170 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 25 |
| Memantine Hcl | Memantine Hcl | 160 | 19 |
| Lisinopril | Lisinopril | 154 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 17 |
| Sertraline Hcl | Sertraline Hcl | 138 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 32 |
| Famotidine | Famotidine | 130 | 15 |
| Losartan Potassium | Losartan Potassium | 128 | 25 |
| Metformin Hcl | Metformin Hcl | 128 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 11 |
| Spironolactone | Spironolactone | 114 | 21 |
| Lorazepam | Lorazepam | 112 | 23 |
| Prednisone | Prednisone | 112 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 11 |
| Omeprazole | Omeprazole | 94 | 21 |
| Myrbetriq | Mirabegron | 92 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 86 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 13 |
| Januvia | Sitagliptin Phosphate | 79 | suppressed |
| Simvastatin | Simvastatin | 78 | suppressed |
| Torsemide | Torsemide | 74 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 73 | suppressed |
| Alprazolam | Alprazolam | 72 | 12 |
| Mirtazapine | Mirtazapine | 71 | suppressed |
| Allopurinol | Allopurinol | 66 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 56 | suppressed |
| Jardiance | Empagliflozin | 55 | suppressed |
| Lidocaine | Lidocaine | 55 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | suppressed |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 26 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | 12 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | suppressed |
| Lovastatin | Lovastatin | 45 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | 16 |
| Digoxin | Digoxin | 44 | suppressed |
| Finasteride | Finasteride | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 42 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Cephalexin | Cephalexin | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 17 |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Clotrimazole | Clotrimazole | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 33 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 15 |
| Lacosamide | Lacosamide | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Ertapenem | Ertapenem Sodium | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 21 |
| Cilostazol | Cilostazol | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 16 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Rayaldee | Calcifediol | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 15 |
| Metolazone | Metolazone | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Mirabegron Er | Mirabegron | 22 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 11 |
| Tradjenta | Linagliptin | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 13 |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Galantamine Er | Galantamine Hbr | 14 | suppressed |
| Imiquimod | Imiquimod | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Dapsone | Dapsone | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Riluzole | Riluzole | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $41.75 · 2 records | Otsuka America Pharmaceutical, Inc. | REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error